Report
Pharvaris R&D day outlines plans to expand deucrictibant opportunity
Yesterday, Pharvaris hosted an R&D call to discuss plans for deucrictibant (oral B2 receptor antagonist) beyond HAE type 1/2. The company believes that deucrictibant could offer good outcomes for patients with normal C1-INH HAE, and this subset of patients is included in the phase 3 programs for on-demand and prophylaxis. In addition, the company pointed to the potential of deucrictibant to address acquired angioedema (AAE), where no approved treatments exist and investigator results demonstrated attack reduction with deucrictibant. Following regulatory alignment, a phase 3 trial for AAE on-demand and prophylaxis is planned for 2025. We reiterate our $32 TP and Buy rating.
Underlying
Pharvaris NV
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.